Evidence map›Paper›PMID 40067607›Full record

ArticleAnnals of surgical oncology2025

Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients.

Zongshun Chen, Jing Zhang, Wei Chen, Xueyi Chen, Da-Lin Lu, Junjie Li

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zongshun ChenSchool of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jing ZhangDepartment of Epidemiology, School of Medicine, Jinan University, Guangdong, China.
Wei ChenSchool of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xueyi ChenDepartment of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Da-Lin LuDepartment of Epidemiology, School of Medicine, Jinan University, Guangdong, China. ludalin999@163.com.ORCID http://orcid.org/0000-0002-6896-6835
Junjie LiDepartment of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. lijunjie@scszlyy.org.cn.ORCID http://orcid.org/0000-0003-4510-8261

Funding

China Primary Health Care Foundation cphcf-2023-158National Natural Science Foundation of China 82003522Natural Science Foundation of Sichuan Province 2023NSFSC0548Wu Jieping Medical Foundation 320.6750.2023-18-99
6 · The paper itself

Abstract

backgroundThis study investigated the association between circulating alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), lactate dehydrogenase (LDH), and gamma-glutamyltransferase (GGT) and the pathologic complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab (H) and pertuzumab (P).

methodsData were collected from 290 patients with HER2-positive breast cancer at Sichuan Cancer Hospital between August 2019 and August 2023. Blood samples were collected to assess the serum enzyme levels, including ALT, AST, CK, LDH, and GGT. Univariable analysis was first performed, followed by multivariable logistic regression, to assess the association of pCR with ALT, AST, CK, LDH, and GGT levels before and after neoadjuvant chemotherapy with H and P.

resultsOf the 290 patients, 174 (60%) achieved pCR after neoadjuvant chemotherapy combined with dual-target therapy. Multivariable logistic regression analysis showed that lower ALT and GGT levels, higher ALT levels before treatment (odds ratio [OR], 2.02; 95% confidence interval [CI] 1.11-3.67; p = 0.02), and higher GGT levels after treatment (OR, 2.04; 95% CI 1.14-3.66; p = 0.017) were significantly associated with pCR. Additionally, neoadjuvant chemotherapy combined with H and P dual-target therapy increased ALT, AST, LDH, and GGT levels in patients' blood.

conclusionBefore neoadjuvant chemotherapy combined with H and P dual-target therapy, ALT levels were associated with pCR. After the treatment, GGT levels were linked to pCR. This treatment regimen was associated with increased blood levels of ALT, AST, LDH, and GGT.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsNeoadjuvant TherapyAdultAgedAlanine TransaminaseAntibodies, Monoclonal, HumanizedAspartate AminotransferasesCreatine KinaseErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up Studiesgamma-GlutamyltransferaseHumansL-Lactate DehydrogenaseAlanine TransaminaseAntibodies, Monoclonal, HumanizedAspartate AminotransferasesBiomarkers, TumorCreatine KinaseERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesgamma-GlutamyltransferaseL-Lactate DehydrogenasepertuzumabTrastuzumabDual-targeted therapyHER2 positive breast cancerNeoadjuvant chemotherapyPathological complete responsePertuzumabSerum enzymesTrastuzumab

Identifiers

PMID40067607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.